Sevelamer Carbonate Tablet
Product Images NDC 72789-562

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 72789-562). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

72789562 Label (72789562)

72789562 Label (72789562)
This description provides details on a medication in tablet form containing Sevelamer carbonate at 800 mg per tablet. It includes information on the manufacturer, dosage instructions, and storage recommendations. The product inquiries are directed to PD-Rx Pharmaceuticals, Inc. It also lists the usual dosage and the number of film-coated tablets in the package. Instructions for storage include maintaining a temperature between 20° to 25°C (68° to 77°F) with permitted excursions between 15° to 30°C (59° to 86°F). The prescription information can be accessed online.*
FDA Label Image

Figure-1 (Fig 1)

Figure-1 (Fig 1)
FDA Label Image

Figure-2 (Fig 2)

Figure-2 (Fig 2)
FDA Label Image

Figure-3 (Fig 3)

Figure-3 (Fig 3)
This text provides data on the percentage of patients with reduction in serum phosphorus levels after treatment with Sevelamer Hydrochloride compared to an active control. It also includes information about the extent of reduction in serum phosphorus levels from the baseline, categorized as worsened, improved, increase, or reduction.*
FDA Label Image

Figure-4 (Fig 4)

Figure-4 (Fig 4)
This text seems to describe a chart or graph showing the change in phosphorus levels from baseline over a certain period of time for a study involving Sevelamer Hydrochloride as the treatment group and an active control group. The data points appear to be provided at different study weeks, ranging from week 10 to week 52.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.